23 research outputs found
Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.
No full textCannabidiol prevents LPSâinduced microglial inflammation by inhibiting ROS/NFâÎșBâdependent signaling and glucose consumption
No full text
Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a lowâTHC Cannabis sativa
No full text
Recommended from our members
Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.
No full textThe purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile
Persistent mucus accumulation: a consequence of delayed bronchial mucous cell apoptosis in RAO-affected horses?
No full textProbable cutaneous adverse drug reaction due to a cannabidiolâcontaining hemp oil product in a dog
No full textRandomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy
No full text
